Please try another search
For the three months ended 31 March 2018, ARMO Biosciences Inc revenues was not reported. Net loss increased from $9.4M to $21.7M. Higher net loss reflects Research & Development Expense - Balan increase from $7.6M to $18.6M (expense), Selling, General & Administrative Expen increase of 64% to $2.6M (expense), Stock-based Compensation in SGA increase from $103K to $485K (expense).
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -22.11 | -14.66 | -28.01 | -9.41 |
Net Income | -21.72 | -14.53 | -27.9 | -9.4 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Total Assets | 175.07 | 56.19 | 70.31 | |
Total Liabilities | 18.21 | 11.65 | 11.74 | |
Total Equity | 156.86 | 44.55 | 58.57 |
Period Ending: | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Mar 31, 2017 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 3 Months |
Cash From Operating Activities | -18.54 | -44.73 | -27.7 | -10.9 |
Cash From Investing Activities | -0.14 | -0.02 | -0.01 | 0 |
Cash From Financing Activities | 134.51 | 67.48 | 67.49 | -0.01 |
Net Change in Cash | 115.84 | 22.74 | 39.78 | -10.91 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review